Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FDA panel recommends J&J COVID-19 booster for all recipients who got first shot

10/15/2021 | 02:55pm EST

A Food and Drug Administration advisory panel on Friday recommended a Johnson & Johnson COVID-19 vaccine booster for all adults who received the original shot, meaning the committee has now approved extra doses for all three vaccines available in the United States.

The FDA'sVaccines and Related Biological Products Advisory Committee voted 19-0 in favor of a second dose of the shot, which is produced by subsidiary Janssen.

The panel advised that people over 18 receive the booster at least two months after their initial immunization of the one-shot Johnson & Johnson vaccine.

At its meeting Friday, the panel heard from experts who recommended a Johnson & Johnson booster for all recipients, instead of just vulnerable Americans, because data show the original vaccine doesn't provide as much protection as the vaccines by Moderna and Pfizer.

The committee held a similar meeting on Thursday, during which it recommended a Moderna booster for older and at-risk Americans. The FDA authorized a Pfizer booster last month.

The FDA isn't obligated to follow the panel's recommendation, but usually does. The soonest it can sign off on the recommendation is next week.

In assessing the proposed booster this week, FDA scientists said they weren't sure about when a second Johnson & Johnson dose should be given. The company recommended between two and six months after the original dose, but the scientists indicated there was a lack of data to determine the best time.

The scientists, however, did say that data indicates that the booster dose would provide additional protection against the virus.

"Although not independently confirmed by FDA from datasets, summaries of the data suggest there may be a benefit in a second dose administered approximately 2 months after the primary dose," the scientists wrote.

Dr. Peter Marks, director of the FDA'sCenter for Biologics Evaluation and Research, said Friday that Johnson & Johnson didn't provide information indicating why a booster might be needed.

"There are data suggesting the effectiveness of the vaccine is actually less robust than the company's presentation here," he said during the meeting.

Friday's evaluation comes two days after a federal study said "mixing and matching" booster doses is safe and offers added protection. That means scientists found that a person who received two original doses of Moderna's vaccine could safely get a Pfizer booster -- or a person who received Pfizer's vaccine could get a Johnson & Johnson booster, even though they are formulated differently and are completely different types of vaccines.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source US Top News

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.46% 159.38 Delayed Quote.1.27%
MODERNA, INC. 1.73% 306.72 Delayed Quote.193.60%
PFIZER, INC. 2.32% 54.27 Delayed Quote.44.09%
All news about JOHNSON & JOHNSON
05:04pJohnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of B..
12/04Covid-19 - Nigeria Approves Booster Doses for Enhanced Protection
12/04Federal Contractor And Subcontractor Vaccine Mandate Temporarily Enjoined In Kentucky, ..
12/03Janssen to Showcase Progress on Respiratory Syncytial Virus (RSV) Vaccine Candidate at ..
12/03Johnson & Johnson's Janssen Says Phase 3b Trial of Active Psoriatic Arthritis Treatment..
12/03JOHNSON & JOHNSON : Latest Phase 3 Data for First-in-Class TREMFYA« (guselkumab) Demonstra..
12/03Johnson & Johnson's Janssen Says Psoriatic Arthritis Trial Meets Objective
12/02Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
12/02Covid-19 - Mobile Vaccination Teams Deployed to Weekly Markets, Inland Regions
12/02Africans Will Get Wider Access to Vaccines in New Distribution Deal
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 251 M - -
Net income 2021 22 542 M - -
Net Debt 2021 493 M - -
P/E ratio 2021 19,2x
Yield 2021 2,62%
Capitalization 420 B 420 B -
EV / Sales 2021 4,46x
EV / Sales 2022 4,15x
Nbr of Employees 134 500
Free-Float 84,3%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 159,38 $
Average target price 184,65 $
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ABBVIE INC.8.18%210 113